Eisai and Biogen completed the rolling submission of a Biologics License Application for their proposed Alzheimer’s disease drug to the U.S. Food and Drug Administration.
Bruised and battered by its failings with the controversial Alzheimer’s drug Aduhelm, Biogen is looking to right the ship with a new helmsman. The company is on the hunt for a new chief executive officer.
Cassava Sciences President and CEO Remi Barbier is hitting back at The New York Times, calling out the venerable newspaper for an alleged one-sided article that he claims misrepresented the research of his company by only using sources who were critical of Cassava.
U.S. Medicare limits coverage for Biogen’s Alzheimer’s drug Published April 7, 2022; 7:40 PM EDT By Deena Beasley April 7 (Reuters) – The U.S. government health plan for people age […]
Biogen announced plans to present data on the company’s portfolio, including the controversial medicine Aduhelm (aducanumab), at the annual Clinical Trials on Alzheimer’s Disease conference (CTAD) scheduled for November 9-12.
An experimental Alzheimer’s drug from Roche and AC Immune failed to slow cognitive and functional decline in a clinical trial, the Swiss companies said, in a fresh setback to efforts to fight the fatal dementia-causing disease.
75 top Alzheimer’s and dementia experts collaborated on a 10-year strategic plan for researchers, policymakers and caregivers May 21, 2020 –– A new report released today by AARP and the […]
Axsome Therapeutics announced that the company’s AXS-05 met the primary endpoint in the ADVANCE-1 Phase II/III clinical trial for agitation in patients with Alzheimer’s disease.
Eagle Pharmaceuticals Inc. and the University of Pennsylvania agreed on terms of a new exclusive worldwide license agreement for the development of dantrolene sodium for the potential treatment of people living with Alzheimer’s disease.
Purchasers of Allergan Plc’s Namenda asked a federal judge to approve a $750 million settlement of claims that the drugmaker conspired to keep generic versions of the Alzheimer’s medication off the market.